Drug Search Results
More Filters [+]

Azasetron

Alternative Names: azasetron
Latest Update: 2024-08-21
Latest Update Note: Clinical Trial Update

Product Description

Azasetron (Serotone) is a potent and selective 5-HT3 receptor antagonist, and classified as benzamide derivative. It has a different chemical structure from indole-type 5-HT3 receptor antagonists such as granisetron, ondansetron, ramosetron and tropisetron. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/10396331/)

Mechanisms of Action: 5-HT3 Antagonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Sensorion
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Azasetron

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

ChiCTR2300078516

N/A

Not yet recruiting

Anesthesia Related

2026-08-31

ChiCTR2300076786

N/A

Not yet recruiting

Unknown

2024-10-20

ChiCTR2200060139

N/A

Not yet recruiting

Chronic Pain|Pain, Postoperative

2023-12-31

ChiCTR2100049246

N/A

Not yet recruiting

Other

2021-12-31

Recent News Events